Penetration of chlorhexidine into human skin by Karpanen, Tarja J. et al.
 1 
Penetration of chlorhexidine into human skin 1 
 2 
Short running title: Skin penetration of chlorhexidine 3 
 4 
T. J. Karpanen1*, T. Worthington1, B. R. Conway1, A. C. Hilton1, T. S. J. Elliott2  and 5 
P. A. Lambert1. 6 
 7 
1. Life& Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK 8 
2. Selly Oak Hospital, University Hospital Birmingham NHS Foundation Trust, 9 
Raddlebarn Road, Selly Oak, Birmingham B29 6JD. 10 
 11 
* Corresponding author. Mailing address: Life and Health Sciences, Aston University, 12 
Aston Triangle, B4 7ET, UK. Tel. (44) 121 204 3951, fax. (44) 121 204 4187. E-mail: 13 
karpantj@aston.ac.uk. 14 
 15 
Key words 16 
Skin permeation, antiseptic, HPLC, Franz diffusion cell, chlorhexidine 17 
ACC
EPT
D
 Copyright © 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
Antimicrob. Agents Chemother. doi:10.1128/AAC.00637-08 
AAC Accepts, published online ahead of print on 1 August 2008
 2 
Abstract 18 
 19 
This study evaluated a model of skin permeation to determine the depth of delivery of 20 
chlorhexidine into full thickness excised human skin following topical application of 2% 21 
(w/v) aqueous chlorhexidine digluconate. Skin permeation studies were performed on 22 
full-thickness human skin using Franz diffusion cells and exposed to chlorhexidine for 2 23 
min, 30 min and 24 h. The concentration of chlorhexidine extracted from skin sections 24 
was determined to a depth of 1500 µm following serial sectioning of the skin using a 25 
microtome and analysis by high performance liquid chromatography. Poor penetration of 26 
chlorhexidine into skin following 2 min and 30 min exposure to chlorhexidine was 27 
observed  (0.157 ± 0.047 and 0.077 ± 0.015 µg/ mg tissue within the top 100 µm) and 28 
levels of chlorhexidine were minimal at deeper skin depths (less than 0.002 µg/ mg tissue 29 
below 300 µm). After 24 h exposure, there was more chlorhexidine within the upper 100 30 
µm sections (7.88 ±1.37 µg/ mg tissue), however the levels remained low (less than 1 µg/ 31 
mg tissue) at depths below 300 µm. There was no detectable penetration through the full 32 
thickness skin. The model presented in this study can be used to assess the permeation of 33 
antiseptic agents through various layers of skin in vitro. Aqueous chlorhexidine 34 
demonstrated poor permeation into the deeper layers of the skin, which may restrict the 35 
efficacy of skin antisepsis with this agent. This study lays the foundation for further 36 
research in adopting alternative strategies for enhanced skin antisepsis in clinical practice. 37 
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Introduction 38 
 39 
Effective skin antisepsis is essential in preventing infections associated with invasive 40 
procedures, such as intravascular catheter insertion or surgery. A range of skin antiseptic 41 
agents are available in the clinical setting, such as povidone-iodine and chlorhexidine 42 
compounds at various concentrations with alcoholic or aqueous solutions. However, 2% 43 
(w/v) chlorhexidine solution is the recommended agent to be used prior to invasive 44 
procedures by the EPIC (Evidence-based practice in infection control) and CDC (Centres 45 
for disease control and prevention) guidelines (18,19). Two percent chlorhexidine 46 
digluconate (CHG) has been shown to significantly reduce intravascular catheter related 47 
infections (14), yet 2% (w/v) CHG in 70% (v/v) isopropyl alcohol (IPA) demonstrates 48 
superior activity compared to aqueous CHG solution in preoperative skin preparation (9) 49 
and in vitro carrier tests (1). However, there is little known about the kinetics of 50 
chlorhexidine skin permeation from either of these solutions (11,25). Microorganisms 51 
colonising the skin not only reside on the skin surface but are also found to inhabit hair 52 
follicles and lower skin depths (8). Many antimicrobial agents exhibit restricted 53 
permeation of the skin (8) and fail to reach the deeper layers, including the hair follicles, 54 
which harbour coagulase negative staphylococci (2,7,8,13,15) and propionibacteria (13). 55 
Commensal microorganisms may therefore persist at the site of incision following skin 56 
antisepsis (4,22) and such resident organisms may cause infection when the protective 57 
skin barrier is breached during surgical procedures (12,20,26). Therefore, effective and 58 
rapid permeation of the applied antiseptic agent into the deeper layers of the skin is 59 
essential in preventing infections associated with invasive procedures.  60 
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The aim of this current study was to use the Franz-cell skin model (6) to 61 
determine the penetration profile for CHG through excised human skin, and to evaluate 62 
the skin permeation of 2% (w/v) aqueous CHG into the skin using this model. 63 
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Materials and methods 64 
 65 
Materials 66 
Chlorhexidine digluconate (CHG), diethylamine (HPLC grade), dimethyl sulphoxide 67 
(DMSO), phosphate buffered saline (PBS), sodium heptane sulphonate (HPLC grade) 68 
and Tween 80 were purchased from Sigma-Aldrich (Dorset, UK). Acetic acid and 69 
methanol (both HPLC grade) were purchased from Fisher Scientific (Leicestershire, UK). 70 
 71 
Skin samples 72 
Full thickness human skin samples were obtained from patients undergoing breast 73 
reduction surgery (The Stephen Kirby Skin Bank, Queen Mary’s Hospital, London, UK) 74 
and full ethical committee approval was obtained prior to this study  (REC 2002/ 169). 75 
The full thickness human skin was frozen on the day of excision and stored at -70˚C until 76 
required. 77 
 78 
Quantification of CHG 79 
High-performance liquid chromatography (HPLC) was used to measure the amount of 80 
CHG in the skin samples obtained during the permeation studies.  The analyses were 81 
performed using an Agilent 1200 series HPLC system (Agilent Technologies, UK). The 82 
samples were run at a flow rate of 1.2 mL/ min at room temperature through a reverse 83 
phase chromatography column (CPS-2 Hypersil 5µm column dimension 150 x 4.6mm 84 
(Thermo Electron Corporation, UK)), with ultraviolet detection at 254 nm. The isocratic 85 
mobile phase consisted of methanol: water mixture (75:25) with 0.005 M sodium heptane 86 
ACC
EPT
ED
 6 
sulphonate and 0.1% (v/v) diethylamine adjusted to pH 4 with glacial acetic acid. The 87 
HPLC method was validated by repeating a series of standardised CHG concentrations 88 
five times and plotting a graph of peak area versus CHG concentration. The level of 89 
detection (LOD) and level of quantification (LOQ) were calculated from the standard 90 
curve according to the following equation: 91 
 92 
LOD= 3 x standard deviation (SD) / slope, and the LOQ= 10x SD/ slope. 93 
 94 
Skin permeation studies 95 
Skin permeation studies were performed with vertical Franz diffusion cells (figure 1). 96 
The receptor compartment was filled with 29 mL of PBS and maintained at 37˚ C by a 97 
circulating water jacket and agitated by stirring with a magnetic bar. Skin samples were 98 
thawed in PBS at room temperature, dried with an absorbent towel and mounted onto 99 
Franz diffusion cells with the stratum corneum (SC) uppermost facing the donor 100 
compartment. The surface area exposed to the test compound was 3.14 cm2 (2 cm in 101 
diameter). All entrapped air was removed between the skin and receptor fluid and the 102 
skin was left to equilibrate for 30 min to reach the skin surface temperature of 32˚C.  103 
Twenty percent (w/v) aqueous CHG was diluted with distilled water and 0.1% (v/v) 104 
Tween 80 to obtain the final test solution 2% (w/v) CHG. One millilitre of test solution 105 
was spread over the skin surface in the donor compartment and the compartment was 106 
sealed with a moisture resistant film (Parafilm M®, Alcan packaging, USA) to prevent 107 
evaporation. One millilitre of receptor fluid was removed every 30 min for 2 h, every 108 
hour between 2 to 6 h and at 8 h, 12 h and 24 h. Fluid removed from the receptor 109 
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compartment was immediately replaced with an equal volume of fresh PBS solution. All 110 
samples were filtered through a 0.45 µm nylon filter (Kinesis, UK) and analysed by 111 
HPLC. The assay was performed in triplicate and on two different donor skin samples. 112 
 113 
CHG penetration profile studies 114 
Excised full thickness human skin samples were mounted onto the Franz diffusion cells 115 
as described above, and exposed to 2% (w/v) CHG for 2 min, 30 min and 24 h. Following 116 
exposure, the skin samples were removed, washed with PBS and dried with an absorbent 117 
towel. The skin samples were immediately sprayed with a cryospray (Bright Instruments) 118 
and frozen at -20˚C. Punch biopsies (7 mm in diameter) were cut from each frozen 119 
sample in triplicate and placed onto a cork disc in embedding compound (Bright 120 
Instruments, Cambs, UK), The frozen samples were sectioned horizontally with a 121 
microtome (Bright Instruments) into 20 µm sections (from the surface to a depth of 600 122 
µm) and 30µm sections (from depths of 600 to 1500 µm). Each section was placed into 123 
an Eppendorf tube and the total weight of each skin sample determined. Chlorhexidine 124 
was extracted from the skin by placing 1 mL of HPLC mobile phase solution into each 125 
tube followed by incubation of the sealed tubes at 60˚C for 1 h. Following this, the 126 
samples were analysed by HPLC and the concentration of CHG (µg/ mg of skin) 127 
determined. Control skin (skin without treatment) was analysed parallel to the test 128 
samples. Effective elution and recovery of CHG from the skin by this method was 129 
confirmed prior to the experiment by injecting a standardised quantity of CHG (128 µg) 130 
into ten skin samples, extracting the CHG and determining the recovered amount (94.4 ± 131 
1.82 %, data not shown).132 
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Results 133 
 134 
HPLC validation 135 
The mean retention time for CHG was 3.6 min. There were no intervening peaks from 136 
endogenous contaminating compounds within skin samples. The HPLC method gave a 137 
linear response (R2 = 0.999) over the concentration range of 0.0039 µg/ mL to 128 µg/ 138 
mL. The level of detection and LOQ were calculated at 0.016 µg/ mL and 0.052 µg/ mL 139 
respectively. 140 
 141 
Skin permeation studies 142 
No CHG was detected in the receptor compartment during the 24 h exposure of excised 143 
full thickness human skin to 2 % (w/v) aqueous CHG. 144 
 145 
CHG retention studies 146 
After 2 min, 30 min and 24 h, concentrations of chlorhexidine within the skin were 147 
highest in the surface 100 µm sections, and reduced below depths of 300 µm (Figures 2 148 
and 3). The concentration of CHG within the top 100 µm sections of skin were 0.157 (± 149 
0.047) µg/ mg tissue and 0.077 (±  0.015) µg/ mg tissue after 2 min and 30 min exposure 150 
to 2% (w/v) CHG respectively (figure 2). The concentration of CHG within deeper layers 151 
(below 300 µm) fell to less than 0.002 µg/ mg tissue following both 2 min and 30 min 152 
exposure. The difference between the amount of chlorhexidine within the top layers 153 
between 2 min and 30 min exposure was not significant (p> 0.05) (student t-test, 154 
INSTAT2, Graphpad, San Diego, CA, USA). The concentration of CHG was 155 
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significantly higher within all skin sections following 24 h exposure to CHG compared to 156 
the shorter exposure times. The concentration of CHG was 7.88 (± 1.37) µg/ mg tissue 157 
within the upper 100 µm sections, and less than 1 µg/ mg of tissue at depths of 300 µm 158 
and below. 159 
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Discussion 160 
 161 
This study demonstrates that 2 % (w/v) chlorhexidine, the antiseptic agent recommended 162 
within EPIC and CDC guidelines for skin antisepsis prior to central venous catheter 163 
(CVC) insertion, poorly permeates into deeper layers of the skin after 2 min and 30 min 164 
exposure to the antiseptic. The concentration of CHG within the upper 100 µm sections 165 
of skin was 0.157 (± 0.047) µg/ mg tissue and 0.077 (± 0.015) µg/ mg tissue after 2 min 166 
and 30 min respectively. If 1 g of tissue is estimated to equal 1 ml, these levels are higher 167 
than the concentrations required to kill many common skin microorganisms such as 168 
S.epidermidis in in vitro conditions (10). Below 300 µm, the CHG concentration 169 
remained less than 0.002 µg/ mg tissue, which may not be effective at eradicating 170 
microorganisms on skin (17), especially microorganisms residing deep in the hair 171 
follicles. Furthermore, chlorhexidine activity is reduced in the presence of organic 172 
compounds, such as fatty acids and at lower pH (16) and therefore may reduce the 173 
efficacy of skin antisepsis with CHG. An exposure time of 2 minutes was used to reflect 174 
the clinical conditions used prior to surgery (5). Although the 2 minute study appears to 175 
show a higher amount of bound chlorhexidine than the 30 minute study, there is 176 
variability in concentrations measured in the top layers, as is expected at the shorter 177 
exposure period (24), and the difference between 2 min and 30 min exposure is not 178 
significant (p> 0.05). It is likely that a steady state has not been reached yet at 2 min. A 179 
similar phenomenon was reported by Wagner et al. (23). Skin was also exposed to 2% 180 
(w/v) CHG for 24 h and the concentration of CHG in the deeper sections, i.e., beyond 181 
300 µm, was less than 1 µg/ mg tissue. These levels of CHG are more than the minimum 182 
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bactericidal concentrations for many skin commensals (10), however this level of CHG 183 
was only obtained after a prolonged contact time of the skin with CHG. In this study no 184 
detectable levels of CHG was recovered from the receptor compartment suggesting that 185 
aqueous CHG does not permeate through the full thickness of excised skin and is retained 186 
within the tissue. These results support previous research on another CHG-based 187 
compound, chlorhexidine phosphanilate, which was also shown not to permeate through 188 
full thickness skin samples (25). 189 
In this study, a model for studying the delivery of CHG into excised full thickness 190 
human skin was evaluated. Skin permeation studies are commonly performed in vitro 191 
with vertical or horizontal diffusion cells using skin or artificial membranes. This study 192 
was performed using vertical diffusion cells (Franz type diffusion cells), to evaluate the 193 
delivery of CHG through excised full thickness human skin. Such conditions mimic the 194 
in vivo environment by maintaining the physiological receptor fluid at body temperature 195 
and the skin surface temperature of 32˚C (6,23). Skin permeation studies generally 196 
evaluate drug delivery through the skin by measuring drug diffusion into the receptor 197 
fluid through the SC or epidermis, which are the main barriers for skin permeation. 198 
However, the use of stripped skin layers, such as isolated SC or epidermal layers, for 199 
drug permeation studies may influence the results with possible retention of the drug in 200 
the dermal layers of the skin will not be considered.  Full thickness skin was used in this 201 
study to determine the location of CHG throughout the skins, rather than studying flux of 202 
the drug through the barrier layers. Following exposure to CHG, the full thickness human 203 
skin was sectioned to a depth of 1500 µm by sequential sectioning with a microtome 204 
producing a total of 60 sections per skin sample. Skin sectioning has been used in many 205 
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previous studies (21), however the SC is often removed by tape stripping prior to 206 
sectioning of the skin. In this study the full thickness skin samples were sectioned 207 
throughout the sample without prior removal of the surface layers. This study 208 
demonstrates that the CHG permeation through the full thickness skin was not linear, 209 
which was expected due to the variation in structure at various layers. The top 100 µm 210 
layer of the skin, which contains SC (average 10- 20 µm thick) and other epidermal 211 
layers (50 – 100 µm thick), contained the highest amount of CHG following exposure to 212 
2% (w/v) CHG over all time points studied. Previous research has shown that the main 213 
permeation barrier for skin absorption is the SC (3,11,25), which is thought to be due to 214 
its high lipid matrix and packed layers of keratinised epithelial cells. Furthermore, this 215 
study found that below 300 µm, at the dermal layer, the level of CHG remained 216 
constantly low. Depending on the body site, dermis contains hair follicles and other skin 217 
appendages, including sebaceous glands and sudoriferous glands (sweat producing 218 
glands), which are of interest in skin antisepsis as they may be niches for microbial 219 
colonisation of the skin following skin antisepsis (7,8). It is generally recognised that skin 220 
antisepsis does not sterilize the skin; our study confirms this and demonstrates that it may 221 
be due to poor permeation of chlorhexidine into the deeper layers of the skin. 222 
In conclusion, this study showed poor permeation of chlorhexidine through 223 
excised full thickness human skin after 2 min and 30 min exposure to aqueous 2 % (w/v) 224 
CHG. The level of CHG were highest within the top 100 µm sections of skin, and 225 
remained consistently low within the deeper layers. Furthermore, the model presented in 226 
this study is a valuable tool in determining a permeation profile for chlorhexidine through 227 
human skin in vitro. This study lays the foundation for further research within this area 228 
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with a view to potentially adopting alternative strategies for enhanced skin antisepsis in 229 
clinical practice. 230 
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 338 
Figure 1. Diagram of Franz diffusion cell. Receptor compartment was filled with PBS, 339 
which was kept at 37˚C by circulating water jacket. The skin was mounted between the 340 
receptor and donor compartment and clamped. The test drug was aliquoted onto the 341 
donor compartment. The drug diffused through the skin was sampled by drawing up 342 
receptor fluid via sampling port.343 
 Sampling port 
Clamp 

 Skin 
Donor compartment 
Receptor compartment 
 Magnetic stirring bar 
Circulating water jacket  
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 344 
Figure 2. Penetration profile showing the location of chlorhexidine (µg/mg tissue) in excised human skin after 2 min and 30 min 345 
exposure to aqueous 2% (w/v) chlorhexidine digluconate (mean ± s.e., n=15). 346 
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 347 
Figure 3. Penetration profile showing the location of chlorhexidine (µg/ mg tissue) in excised human skin after 2 min and 30 min 348 
(n=15) and 24 h (n=30) exposure to aqueous 2% (w/v) chlorhexidine digluconate (mean ± s.e).  349 
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